Given similar talk from the company last year re not needing a...

Given similar talk from the company last year re not needing a capital raise and then doing one towards the end of Feb only to announce FDA failure a couple of weeks later makes me a bit uneasy about this one. Has a sense of déjà vu about it.

I guess it was just hope that we would get Medgate and other deals over the line in the coming months and be in a position to raise at a higher price if needed.  

Having said that, I believe @pilko3 has a very valid point. Negotiating with crucial partners that have the ability to give us the credibility we desperately need to make the Telehealth world sit up and take notice, with a progressively weak cash position is certainly not a great place to be.

Firstly your potential partner wants to feel comfortable you can keep the lights on beyond the full integration into their network and not suffer the embarrassment of having what should be a very exciting addition to their offering disappear.

Secondly you don’t want to be in a position where they think you’re desperate and therefore easy to bully into accepting a lower $ figure per test.  

I am an optimist and like to think it’s the latter. Can’t wait for the day when one of these trading halts actually leads to an announcement that blows my mind rather than making me feel deflated time and time again.   

I have supported this stock for years but unfortunately  admit i’m beginning to tire.